Cancer Cell：西湖大学郭天南团队等绘制泛癌种蛋白质组图谱，覆盖22种癌症类型

Core Viewpoint - The article discusses the development of a large-scale Pan-Cancer Proteome Atlas (TPCPA) that aims to enhance the understanding of cancer biology and identify therapeutic targets and biomarkers through mass spectrometry-based analysis of protein expression across various cancer types [2][4]. Group 1: Research Overview - The TPCPA covers 22 cancer types, including 18 solid tumors and 4 non-solid tumors, analyzing 999 primary tumor samples and quantifying 9,670 proteins [5][6]. - The study identifies multiple pan-cancer and specific protein biomarkers, potential therapeutic targets, and classifiers for cancer subtypes [2][6]. Group 2: Methodology and Findings - The research utilizes data-independent acquisition mass spectrometry (DIA-MS) to construct the proteome atlas, facilitating a comprehensive analysis of protein expression characteristics both inter- and intra-cancer types [4][6]. - The study highlights specific E3 ubiquitin ligases, such as HERC5 and RNF5, that are highly expressed in esophageal and liver cancers, respectively, as potential targets for protein-targeted degradation therapies [6]. Group 3: Cancer Subtype Classification - An analysis of 195 colorectal cancer cases led to the identification of consensus molecular subtypes (CMS) and two immune subtypes with prognostic value [7]. - A cancer subtype classifier based on 75 proteins was developed, demonstrating excellent performance (AUC greater than 0.98) in internal validation and four independent cohorts, including metastatic cancers [7]. Group 4: Data Accessibility - The research team has made all TPCPA data publicly available for free access and use through a dedicated portal [9].